Data / Research funding / Cystic Fibrosis
Cystic Fibrosis: 358 NIH awards ($350M) to 124 organizations
358 NIH awards ($350M) in the NIH spending category Cystic Fibrosis, to 124 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
358 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $11,172,471 | August 15, 2022 | July 31, 2027 | BOUCHER, RICHARD CHARLES | reporter.nih.gov |
| DartCF: The Dartmouth Cystic Fibrosis Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,832,026 | July 1, 2018 | August 31, 2030 | MADDEN, DEAN R | reporter.nih.gov |
| Early Pathogenesis of Cystic Fibrosis Related Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $4,452,977 | April 30, 2021 | March 31, 2024 | ENGELHARDT, JOHN F | reporter.nih.gov |
| Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,919,631 | February 3, 2021 | January 31, 2027 | CLEVELAND, ZACKARY I | reporter.nih.gov |
| Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $3,727,321 | April 13, 2021 | March 31, 2027 | KIM, AMY S | reporter.nih.gov |
| Estimating the risk for and severity of respiratory infections attributable to CFTR heterozygosity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,719,716 | April 1, 2021 | March 31, 2027 | POLGREEN, PHILIP M | reporter.nih.gov |
| Inhaled tigecycline therapy for pulmonary M. abscessus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,573,339 | June 29, 2021 | May 31, 2027 | GONZALEZ-JUARRERO, MERCEDES | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Role of mucin in lung homeostasis and pathophysiology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,219,550 | August 1, 2009 | April 30, 2027 | EVANS, CHRISTOPHER M | reporter.nih.gov |
| Role of Ezrin in Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,162,244 | July 1, 2021 | June 30, 2027 | BRUSCIA, EMANUELA MARINA | reporter.nih.gov |
| Pathogenic monocyte response to chronic lung inflammation in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,086,283 | January 1, 2022 | November 30, 2026 | BRUSCIA, EMANUELA MARINA | reporter.nih.gov |
| Extracellular vesicle-driven neutrophilic inflammation in cystic fibrosis lungs | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,999,664 | July 1, 2022 | June 30, 2026 | TIROUVANZIAM, RABINDRA MARIE-JEAN | reporter.nih.gov |
| Develop combinatorial non-viral and viral CRISPR delivery for lung diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,938,558 | September 10, 2018 | August 31, 2024 | GAO, GUANGPING | reporter.nih.gov |
| Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,779,536 | December 15, 2017 | December 31, 2025 | SORSCHER, ERIC J | reporter.nih.gov |
| Biological mechanisms and consequences of efficient extracellular electron transfer in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,726,511 | May 8, 2017 | June 30, 2028 | NEWMAN, DIANNE K | reporter.nih.gov |
| Autophagy-mediated mucin degradation is necessary for resolution of mucous metaplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,704,621 | April 23, 2021 | March 31, 2027 | DICKINSON, JOHN DAVID | reporter.nih.gov |
| Sensing living P. aeruginosa using D-alanine derived radiotracers | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,693,051 | May 1, 2021 | January 31, 2026 | WILSON, DAVID M | reporter.nih.gov |
| Mechanisms of mucociliary dysfunction in cystic fibrosis related diabetes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,678,041 | April 1, 2021 | March 31, 2026 | SALATHE, MATTHIAS A | reporter.nih.gov |
| Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,675,883 | September 17, 2012 | June 30, 2026 | KELLY, ANDREA BRIDGET | reporter.nih.gov |
| Monoclonal Antibody to Combat Pseudomonas Aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,646,807 | August 15, 2023 | July 31, 2028 | GOLDBERG, JOANNA B | reporter.nih.gov |
| Repurposing antimalarials for the treatment of NTM infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,633,094 | June 15, 2022 | May 31, 2027 | JACKSON, MARY | reporter.nih.gov |
| In vivo delivery of engineered tRNAs for suppression of nonsense mutations | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,591,222 | April 10, 2021 | March 31, 2026 | LUECK, JOHN D. | reporter.nih.gov |
| A Dietary Intervention to Improve Glucose Tolerance in Adults with Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,582,505 | September 15, 2022 | May 31, 2027 | ALVAREZ, JESSICA ALEJANDRA | reporter.nih.gov |
| Delivering inhalable nanoparticles containing AI-optimized CFTR mRNA with a novel microfluidic device for treatment of CF | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,575,533 | April 1, 2019 | April 30, 2029 | SAHAY, GAURAV | reporter.nih.gov |
| Prevention of Ototoxicity with Effective Monitoring (POEM) Pharmacokinetic and Auditory Linkages | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2024 | $2,538,254 | September 1, 2020 | August 31, 2025 | HUNTER, LISA LEIGH | reporter.nih.gov |
| Altered Circadian Rhythm Regulation in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,492,315 | April 15, 2022 | March 31, 2027 | KELLEY, THOMAS J | reporter.nih.gov |
| Multi-scale model of microbial phenotype modulation by mucins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,480,426 | June 1, 2020 | May 31, 2026 | PAPIN, JASON | reporter.nih.gov |
| Let-7b in Extracellular Vesicles Secreted by Bronchial Epithelial Cells Increases the Antibiotic Sensitivity of Pseudomonas | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,409,204 | December 15, 2020 | November 30, 2025 | STANTON, BRUCE A. | reporter.nih.gov |
| Optimizing Surgical Transplant of CFTR Gene-Corrected Human Basal Stem Cells to the Upper Airway | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,392,495 | March 1, 2021 | January 31, 2027 | NAYAK, JAYAKAR V | reporter.nih.gov |
| Regional monitoring of CF lung disease after changes in mechanical airway-clearance treatment | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,387,402 | May 1, 2016 | April 30, 2028 | WOODS, JASON C | reporter.nih.gov |
| A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,345,744 | December 27, 2022 | November 30, 2027 | PICKING, WENDY L. | reporter.nih.gov |
| Modulation of Lung Disease by Genetic/Epigenetic Profiling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,332,500 | April 1, 2010 | May 31, 2027 | BALCH, WILLIAM EDWARD | reporter.nih.gov |
| Contribution of pulmonary ionocytes and neuroendocrine cells to ion transport-mediated airway surface liquid maintenance | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,318,122 | July 25, 2021 | April 30, 2027 | BRATCHER, PRESTON E | reporter.nih.gov |
| SCGE Disease Models Studies Supplement: Repair of a CFTR Nonsense Mutation Using Adenine Base Editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,297,248 | September 7, 2018 | August 31, 2024 | MCCRAY, PAUL B | reporter.nih.gov |
| Life-long phenotypic correction of CF airways | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,290,437 | August 1, 2017 | February 28, 2027 | SINN, PATRICK L | reporter.nih.gov |
| Metabolic Basis of Bacterial Community Function in the Cystic Fibrosis Airway | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,268,565 | June 2, 2021 | May 31, 2026 | O'TOOLE, GEORGE A. | reporter.nih.gov |
| A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,267,449 | August 15, 2025 | July 31, 2027 | DONN, KARL H | reporter.nih.gov |
| Preparation for lung transplant discussions and decisions among people with cystic fibrosis | NIH | National Institute of Nursing Research | 2023 to 2025 | $2,255,861 | April 19, 2023 | January 31, 2028 | RAMOS, KATHLEEN JESSICA | reporter.nih.gov |
| Understanding in vivo antibiotic resistance in diverse Pseudomonas aeruginosa populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,254,202 | April 9, 2021 | March 31, 2027 | DIGGLE, STEPHEN PAUL | reporter.nih.gov |
| The Role of Airway Mucus in Infection and Inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,217,943 | June 1, 2021 | May 31, 2027 | BIRKET, SUSAN ELIZABETH | reporter.nih.gov |
| Biology of Submucosal Gland Stem Cells in the Airway | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,198,254 | June 20, 2022 | May 31, 2025 | ENGELHARDT, JOHN F | reporter.nih.gov |
| Role of disrupted ASL pH regulation in small airways in CF lung disease pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,193,211 | August 15, 2021 | July 31, 2025 | LI, XIAOPENG | reporter.nih.gov |
| Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,189,214 | December 15, 2020 | November 30, 2025 | ROWE, STEVEN MARK | reporter.nih.gov |
| Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,158,270 | September 1, 2022 | August 31, 2027 | SINGH, PRADEEP K | reporter.nih.gov |
| The CFTR Interactome | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,146,994 | August 5, 2022 | July 31, 2027 | YATES III, JOHN R | reporter.nih.gov |
| Contribution of Small Airways to Mucociliary Transport Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,116,379 | April 1, 2023 | February 29, 2028 | ABOU ALAIWA, MAHMOUD | reporter.nih.gov |
| Alveolar responses to viral lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,088,426 | June 20, 2022 | May 31, 2027 | HOOK, JAIME LYNN | reporter.nih.gov |
| Novel Strategies to Clear Bacteria from the CF Lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $2,072,426 | March 24, 2023 | July 31, 2024 | AHMAD, SAIRA | reporter.nih.gov |
| Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variants | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,052,439 | September 1, 2023 | May 31, 2027 | SCHLEBACH, JONATHAN PATRICK | reporter.nih.gov |
| Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,048,532 | February 1, 2023 | January 31, 2028 | KAZMERSKI, TRACI M | reporter.nih.gov |
| Pro-Inflammatory Stem Cell Variants in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,034,476 | February 1, 2022 | January 31, 2026 | MCKEON, FRANK D. | reporter.nih.gov |
| Molecular Genetics of Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,030,500 | May 1, 1991 | April 30, 2027 | CUTTING, GARRY R | reporter.nih.gov |
| Emerging antibiotic resistance in Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,001,153 | February 1, 2019 | January 31, 2025 | YU, EDWARD W | reporter.nih.gov |
| Inhibition of an Apical cAMP/cGMP Transporter (MRP4) in the Gut Induces Diarrhea | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,953,915 | August 20, 2009 | May 31, 2028 | NAREN, ANJAPARAVANDA P | reporter.nih.gov |
| Targeting SGLTs for liver disease in a rabbit model of cystic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,904,215 | July 1, 2023 | April 30, 2027 | XU, JIE | reporter.nih.gov |
| Coordination of chaperone interactions that dictate protein folding and trafficking | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,904,159 | September 1, 2019 | November 30, 2029 | PLATE, LARS | reporter.nih.gov |
| An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,899,172 | May 24, 2021 | August 31, 2026 | EMAMINEJAD, SAM | reporter.nih.gov |
| COVID-19 airway inflammation is due to Spike inhibition of CFTR signaling | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,873,689 | January 15, 2023 | December 31, 2026 | POLLARD, HARVEY BRUCE | reporter.nih.gov |
| Real-Time Assessment of Lung Structure and Function in CF Patients using Electrical Impedance Tomography | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,851,624 | April 1, 2019 | August 31, 2024 | MUELLER, JENNIFER LYNN | reporter.nih.gov |
| Pre-Clinical Evaluation of IRE1beta as a Novel Therapeutic Target for Cystic Fibrosis Airway Mucus Production | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,848,920 | September 15, 2021 | August 31, 2025 | RIBEIRO, CARLA MARIA PEDROSA | reporter.nih.gov |
| Translational Program in CFTR-Related Airway Diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,835,932 | January 15, 2017 | September 30, 2022 | ROWE, STEVEN MARK | reporter.nih.gov |
| Clinical studies of a bionic pancreas for automated glucose management in cystic fibrosis-related diabetes mellitus | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,831,354 | January 16, 2019 | December 31, 2024 | PUTMAN, MELISSA SUSAN | reporter.nih.gov |
| Mucociliary innate defense mechanism in the human distal airway | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,819,157 | February 1, 2023 | June 30, 2026 | OKUDA, KENICHI | reporter.nih.gov |
| A novel highly stable pancreatic enzyme replacement therapy to improve outcomes for patients with pancreatic insufficiency. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $1,796,643 | August 5, 2022 | July 31, 2023 | GALLOTTO, ROBERT | reporter.nih.gov |
| Targeting fibroblast growth factor receptors in cystic fibrosis-associated airway inflammation and mucociliary dysfunction | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,751,257 | February 1, 2022 | January 31, 2027 | KRICK, STEFANIE | reporter.nih.gov |
| Photochemical Generation of Gas Phase Nitric Oxide from Immobilized S-Nitrosothiols for Biomedical Applications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,730,175 | September 1, 2019 | July 31, 2025 | WOLF, ALEXANDER KEITH | reporter.nih.gov |
| Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,722,576 | February 15, 2020 | June 30, 2024 | REED, MATTHEW | reporter.nih.gov |
| The role of anaerobic microbiota in cystic fibrosis airway disease trajectory | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,695,360 | July 14, 2023 | June 30, 2028 | HUNTER, RYAN COULSON | reporter.nih.gov |
| A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,679,323 | September 15, 2020 | August 31, 2025 | LAMICHHANE, GYANU | reporter.nih.gov |
| The Trojan Horse Hypothesis: Neutrophil Elastase Reprograms Macrophage Function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,646,493 | September 1, 2020 | August 31, 2025 | VOYNOW, JUDITH A | reporter.nih.gov |
| C-di-AMP signaling in S. aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,646,471 | February 1, 2019 | January 31, 2025 | WOODWARD, JOSHUA | reporter.nih.gov |
| Cystic Fibrosis Gene Therapy with adeno-associated viral vectors | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,630,607 | July 1, 2024 | April 30, 2029 | CEBOTARU, LIUDMILA | reporter.nih.gov |
| Understanding alterations to mucus composition and function in asthma | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,614,918 | July 1, 2022 | April 30, 2027 | DUNCAN, GREGG | reporter.nih.gov |
| Controlling the core airway mucin secretion machinery to prevent pathophysiology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,611,504 | September 1, 2015 | March 31, 2024 | DICKEY, BURTON F | reporter.nih.gov |
| Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic Applications | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,576,071 | April 5, 2021 | March 31, 2024 | GAO, XUE | reporter.nih.gov |
| The Georgia Cystic Fibrosis Data Warehouse | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,560,854 | March 1, 2024 | February 28, 2029 | STECENKO, ARLENE A | reporter.nih.gov |
| Development of AAV vectors for CF therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,555,000 | December 15, 2020 | November 30, 2025 | SAMULSKI, RICHARD J | reporter.nih.gov |
| SonoHeal: Smart Resonating Closed-loop Airway Clearance Technology | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,552,834 | April 1, 2020 | November 30, 2025 | BISWAS, RAJOSHI | reporter.nih.gov |
| Nonviral delivery techniques for in vivo prime editing | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,551,000 | February 1, 2022 | January 31, 2027 | ANDERSON, DANIEL G | reporter.nih.gov |
| Acquired CFTR Dysfunction in Alcohol-related Lung Pathology | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,544,404 | January 1, 2020 | December 31, 2024 | RAJU, S.VAMSEE | reporter.nih.gov |
| Identifying breath biomarkers for S. aureus methicillin resistance and small colony variants | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,541,576 | April 1, 2021 | March 31, 2026 | BEAN, HEATHER DENISE | reporter.nih.gov |
| Testing the hypothesis that microbial energetic hijacking of the CF immune response selects for specific pathogens during lung function decline- Diversity Supplement | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,537,625 | June 1, 2020 | April 30, 2024 | NEWMAN, DIANNE K | reporter.nih.gov |
| Resue of CF phagocyte function with CFTR modulator therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,528,557 | April 1, 2022 | March 31, 2027 | GUGLANI, LOKESH | reporter.nih.gov |
| Amelogenesis and Ion Transport | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $1,516,557 | March 15, 2021 | February 28, 2025 | PAINE, MICHAEL LANSDELL | reporter.nih.gov |
| miR-145 target site blockade is a selective strategy to enhance CFTR restoration and readthrough | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,485,000 | September 1, 2021 | August 31, 2026 | HARRIS, WILLIAM THOMAS | reporter.nih.gov |
| Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,482,032 | August 1, 2018 | April 30, 2025 | SORSCHER, ERIC J | reporter.nih.gov |
| Cooperation and antagonism in polymicrobial infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,477,492 | June 4, 2024 | April 30, 2029 | WOZNIAK, DANIEL J | reporter.nih.gov |
| Pulmonary and pancreatic response to cystic fibrosis modulator therapy in young children | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,437,134 | May 15, 2024 | April 30, 2029 | STECENKO, ARLENE A | reporter.nih.gov |
| Continuation of ChiLDReN, the Childhood Liver Disease Research Network: Indiana University | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,430,001 | September 10, 2009 | May 31, 2025 | MOLLESTON, JEAN PAPPAS | reporter.nih.gov |
| Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,426,590 | July 1, 2020 | May 31, 2026 | CEBOTARU, LIUDMILA | reporter.nih.gov |
| Nanodelivery of functional proteins to phagosomal membranes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,407,916 | March 9, 2015 | February 28, 2025 | NELSON, DEBORAH J. | reporter.nih.gov |
| Decoding interspecies signaling networks and the biogeography of polymicrobial infections | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,394,109 | August 18, 2021 | June 30, 2027 | LIMOLI, DOMINIQUE | reporter.nih.gov |
| R01- Mapping environmental contributions to rapid lung disease progression in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,388,194 | January 18, 2019 | December 31, 2023 | SZCZESNIAK, RHONDA | reporter.nih.gov |
| Field Study to Understand Progression of Chronic Airway Infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,385,258 | August 7, 2019 | July 31, 2024 | SINGH, PRADEEP K | reporter.nih.gov |
| Controlled Photochemical Release of Nitric Oxide for Biomedical Applications | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,381,168 | June 15, 2020 | February 28, 2025 | SCHWENDEMAN, STEVEN P. | reporter.nih.gov |
| Applying Spatial Covariance to Understand Human Variation in Genetic Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,372,500 | August 1, 2023 | April 30, 2027 | BALCH, WILLIAM EDWARD | reporter.nih.gov |
| Impact of Pseudomonas aeruginosa cytochrome P450 enzymes and secondary metabolites on drug metabolism and disposition in the cystic fibrosis patient | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,370,302 | December 11, 2023 | October 31, 2028 | LAMPE, JED NOAH | reporter.nih.gov |
| TMEM16A in human airway disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,363,360 | April 1, 2024 | March 31, 2028 | BRETT, THOMAS JOHN | reporter.nih.gov |
| Sinus Disease in Young Children with Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,361,416 | July 15, 2024 | June 30, 2026 | BESWICK, DANIEL M | reporter.nih.gov |
| Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,338,807 | July 17, 2019 | June 30, 2025 | QUINN, ROBERT ANDREW | reporter.nih.gov |
| Regulation of viral-bacterial co-infections by immunometabolism | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,326,538 | September 1, 2024 | June 30, 2028 | BOMBERGER, JENNIFER MELINDA | reporter.nih.gov |
| Quinolone and acyl-homoserine lactone quorum sensing in chronic P. aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,315,260 | July 6, 2023 | June 30, 2028 | DANDEKAR, AJAI | reporter.nih.gov |
| Metallobiochemistry of innate immunity and bacterial physiology | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,295,891 | September 20, 2017 | August 31, 2025 | NOLAN, ELIZABETH M | reporter.nih.gov |
| Investigating of the Mechanisms of Action of CFTR Correctors in RescuingDelta F508-CFTR | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,287,799 | July 1, 2020 | June 30, 2025 | NAREN, ANJAPARAVANDA P | reporter.nih.gov |
| Adenine Base Edited Correction of Cystic Fibrosis Airways | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,276,634 | January 1, 2024 | December 31, 2027 | SINN, PATRICK L | reporter.nih.gov |
| Development of novel approaches for gene editing therapies of cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,265,812 | August 10, 2024 | April 30, 2028 | QIU, JIANMING | reporter.nih.gov |
| ENsuring ACcess to optimal Therapy in CF: ENACT study | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,234,806 | July 17, 2024 | June 30, 2029 | GUIMBELLOT, JENNIFER S | reporter.nih.gov |
| Modulation of Ca2+ -activated K+ channels by CFTR Correctors | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,225,406 | August 1, 2024 | April 30, 2028 | DEVOR, DANIEL C | reporter.nih.gov |
| Advancing Symptom Science and Management in Cystic Fibrosis: Biological, Social, and Clinical Mechanisms | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,221,885 | December 15, 2023 | November 30, 2028 | KAVALIERATOS, DIONYSIOS | reporter.nih.gov |
| C-terminal proteolysis in the Pseudomonas aeruginosa cell envelope | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,212,063 | January 1, 2018 | December 31, 2024 | DARWIN, ANDREW J. | reporter.nih.gov |
| Mechanisms of Impaired Inflammation Resolution in Cystic Fibrosis Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,210,172 | August 1, 2024 | April 30, 2028 | ASHARE, ALIX | reporter.nih.gov |
| Modeling the mucosal glycopeptide mesh for improved disease understanding and mucin-inspired biomaterial design | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,198,958 | September 20, 2023 | July 31, 2028 | CHAKRABORTY, SRIRUPA | reporter.nih.gov |
| The Impact of the Cystic Fibrosis infection environment on biofilm development of nontuberculous mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,181,661 | March 3, 2023 | February 29, 2028 | DEPAS, WILLIAM H. | reporter.nih.gov |
| Host microbiota and airway mucus: a novel paradigm for lung defense and immune homeostasis during early post-natal development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,166,250 | February 15, 2020 | November 30, 2024 | LIVRAGHI-BUTRICO, ALESSANDRA MARIA | reporter.nih.gov |
| The role of mucus and pulmonary surface interactions in lung defense | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,166,250 | July 3, 2015 | June 30, 2025 | BUTTON, BRIAN M | reporter.nih.gov |
| Chaperone Actions in CFTR Biogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,158,100 | July 1, 2004 | March 31, 2026 | GOETZMAN, ERIC S | reporter.nih.gov |
| Neutrophil hyperexocytosis and hypochlorous acid exposure in early cystic fibrosis lung disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,155,561 | December 1, 2022 | November 30, 2026 | CHANDLER, JOSHUA D | reporter.nih.gov |
| Mucin Glycans in the Regulation of Microbial Virulence | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,126,392 | September 30, 2013 | January 31, 2024 | RIBBECK, KATHARINA | reporter.nih.gov |
| Vaccines to counter emerging antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,121,304 | May 1, 2018 | April 30, 2023 | PICKING, WENDY L. | reporter.nih.gov |
| Innate Immune Defect and Neutrophilic Inflammation in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,108,275 | September 1, 2020 | July 31, 2025 | WANG, GUOSHUN | reporter.nih.gov |
| CFTR modulates innate immune response in biliary epithelium: Role in the pathogenesis and treatment of Cystic-Fibrosis-related liver disease. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,093,088 | May 1, 2013 | July 31, 2024 | STRAZZABOSCO, MARIO | reporter.nih.gov |
| Estrogen-mediated effects on neutrophil function and airway inflammatory response | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,085,097 | September 17, 2024 | June 30, 2028 | JAIN, RAKSHA | reporter.nih.gov |
| The Role of Neutrophils in Cystic Fibrosis Pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,074,576 | September 5, 2025 | August 31, 2027 | WANG, GUOSHUN | reporter.nih.gov |
| Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,053,550 | April 10, 2017 | March 31, 2023 | STOLTZ, DAVID A | reporter.nih.gov |
| Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | September 11, 2025 | August 31, 2027 | STASKO, NATHAN ALLAN | reporter.nih.gov |
| Bacterial Cell Wall Composition and the Influence of Antibiotics | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $997,488 | September 1, 2016 | May 31, 2025 | CEGELSKI, LYNETTE S | reporter.nih.gov |
| Revisiting alginate paradigms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $976,284 | November 3, 2017 | October 31, 2023 | WOZNIAK, DANIEL J | reporter.nih.gov |
| Stimulation of Ribosomal Frameshifting by Cotranslational Membrane Protein Folding and Misfolding | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $929,802 | February 1, 2021 | December 31, 2023 | SCHLEBACH, JONATHAN PATRICK | reporter.nih.gov |
| Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds | NIH | National Center for Advancing Translational Sciences | 2021 | $888,678 | January 15, 2019 | July 31, 2023 | JULIANO, RUDOLPH | reporter.nih.gov |
| Predictive Molecular Markers of Lung Function Decline | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $877,827 | May 1, 2019 | March 31, 2025 | ZIADY, ASSEM G | reporter.nih.gov |
| Mechanisms of Islet Failure in CF | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $870,781 | September 19, 2024 | July 31, 2029 | HULL-MEICHLE, REBECCA LUCY | reporter.nih.gov |
| Epigenetic Modulation of Cellular Senescence in the Cystic Fibrosis Lung | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $869,259 | April 1, 2024 | February 29, 2028 | SANDERS, YAN | reporter.nih.gov |
| Characterization of a novel post-transcriptional regulator in P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $868,776 | February 25, 2025 | January 31, 2030 | DOVE, SIMON L | reporter.nih.gov |
| Correcting Pathogenic TGF beta Activity in the Airway | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $858,376 | February 1, 2019 | December 31, 2023 | SWIATECKA-URBAN, AGNIESZKA | reporter.nih.gov |
| Dartmouth Cystic Fibrosis Training Program | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $857,321 | March 1, 2017 | February 29, 2028 | O'TOOLE, GEORGE A. | reporter.nih.gov |
| Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis- Supplement | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $856,198 | July 1, 2023 | May 30, 2026 | PIOTROWSKI-DASPIT, ALEXANDRA SARAH ANNUKKA | reporter.nih.gov |
| Defining the role of respiratory gland patterning in rhinosinusitis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $855,096 | September 1, 2022 | August 31, 2025 | MAY, ALISON | reporter.nih.gov |
| Genetics, glycemic control and the microbiome in cystic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $852,688 | September 15, 2020 | June 30, 2026 | BRENNER, LAURA N | reporter.nih.gov |
| Underlying chromatin architecture defines functionality for CFTR expression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $847,500 | September 20, 2018 | August 31, 2024 | WALSH, MARTIN JOHN | reporter.nih.gov |
| Using Induced Pluripotent Stem Cells to Characterize Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $839,700 | June 1, 2021 | May 31, 2026 | WANG, RUOBING | reporter.nih.gov |
| Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $838,918 | August 1, 2019 | July 31, 2024 | MILLA, CARLOS | reporter.nih.gov |
| Inhibiting the cystic fibrosis transmembrane conductance regulator (CFTR) in the cervix as a novel approach to non-hormonal contraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $835,779 | February 1, 2024 | January 31, 2027 | HAN, LEO LIU | reporter.nih.gov |
| Molecular Pathophysiology of Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $830,776 | September 30, 1999 | April 30, 2024 | HWANG, TZYH-CHANG | reporter.nih.gov |
| TGF-Beta Regulates CFTR-Mediated Airway Smooth Muscle Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $820,800 | February 1, 2021 | January 31, 2026 | KRAMER, ELIZABETH L | reporter.nih.gov |
| Prospective Longitudinal Assessment of Culture-Independent Molecular Airway Markers of Nontuberculous Mycobacteria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $820,000 | January 23, 2019 | November 30, 2023 | NICK, JERRY A | reporter.nih.gov |
| Rescue of multiorgan pathophysiology by adeno-associated virus 1 gene therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $818,750 | September 1, 2021 | August 31, 2025 | CEBOTARU, LIUDMILA | reporter.nih.gov |
| Deciphering the role of the Cystic Fibrosis Transmembrane Receptor (CFTR) in dietary fatty acid transport in the small intestine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $812,621 | September 15, 2025 | July 31, 2030 | KOHAN, ALISON BLOOM | reporter.nih.gov |
| Investigating pulmonary ionocyte function and development using iPSCs | NIH | National Heart, Lung, and Blood Institute | 2025 | $809,162 | September 15, 2025 | June 30, 2030 | WANG, RUOBING | reporter.nih.gov |
| Quantitation and Spatial Registration of Airways Dysfunction with Dynamic 19F MRI in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $804,052 | September 10, 2020 | August 31, 2025 | GORALSKI, JENNIFER L | reporter.nih.gov |
| Selenocyanate as a novel treatment of cystic fibrosis lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $795,886 | January 1, 2019 | November 30, 2023 | DAY, BRIAN J | reporter.nih.gov |
| Evolved cefiderocol resistance and cross protection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $794,849 | February 25, 2025 | January 31, 2030 | JORTH, PETER ALLAN | reporter.nih.gov |
| Phase 1 trial of inhaled tobramycin in very preterm infants with bronchopulmonary dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $792,000 | August 20, 2021 | July 31, 2025 | DOWNES, KEVIN JAMES | reporter.nih.gov |
| Investigating the chromatin remodeling functions of polyphosphate condensates in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $779,915 | May 5, 2025 | April 30, 2030 | RACKI, LISA R | reporter.nih.gov |
| The role of CFTR during macrophage-mediated killing of bacteria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,713 | April 1, 2020 | August 18, 2022 | KOPP, BENJAMIN T | reporter.nih.gov |
| Decoding interspecies signaling networks and the biogeography of polymicrobial infections | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $772,502 | August 18, 2021 | February 29, 2024 | LIMOLI, DOMINIQUE | reporter.nih.gov |
| Antibiotic activities against S. aureus during P. aeruginosa co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $769,472 | January 1, 2018 | December 31, 2022 | CONLON, BRIAN PATRICK | reporter.nih.gov |
| The NET Impact on Lung Epithelia in Cystic Fibrosis and Mucoobstruction | NIH | National Heart, Lung, and Blood Institute | 2025 | $756,875 | January 1, 2025 | December 31, 2029 | HUDOCK, KRISTIN MARA | reporter.nih.gov |
| Pharmacogenomic discovery of therapeutic targets for corrector-refractory cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $750,672 | December 10, 2024 | November 30, 2028 | KOPITO, RON R | reporter.nih.gov |
| Arsenic related cystic fibrosis | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $749,691 | February 1, 2018 | January 31, 2024 | MAZUMDAR, MAITREYI | reporter.nih.gov |
| A universal genome editing strategy to develop an airway stem cell therapy for cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $747,000 | September 1, 2022 | August 31, 2025 | VAIDYANATHAN, SRIRAM | reporter.nih.gov |
| Imaging cotranslational protein folding with high spatiotemporal resolution in living cells | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $746,998 | April 1, 2021 | January 31, 2026 | ZHAO, NING | reporter.nih.gov |
| Modulation of ribosome velocity as a means to rescue refractory CF-causing variants | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $746,997 | September 1, 2021 | August 31, 2024 | OLIVER, KATHRYN E | reporter.nih.gov |
| Using base editing to investigate CFTR polymorphisms in lung diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $746,995 | June 1, 2023 | May 31, 2026 | JIANG, TINGTING | reporter.nih.gov |
| Biology of Submucosal Gland Stem Cells in the Airway | NIH | National Heart, Lung, and Blood Institute | 2025 | $740,192 | June 20, 2022 | May 31, 2027 | ENGELHARDT, JOHN F | reporter.nih.gov |
| The role of CFTR during macrophage-mediated killing of bacteria | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $737,301 | April 1, 2020 | March 31, 2026 | KOPP, BENJAMIN T | reporter.nih.gov |
| Mechanisms linking CFTR to dysregulated barrier function, insulin receptor function, and glucose transport in the CF lung | NIH | National Heart, Lung, and Blood Institute | 2025 | $730,494 | February 1, 2025 | December 31, 2029 | MCCARTY, NAEL A | reporter.nih.gov |
| Development of a versatile paired prime editing toolkit for CFTR gene correction | NIH | National Heart, Lung, and Blood Institute | 2025 | $730,268 | August 15, 2025 | May 31, 2030 | JIANG, TINGTING | reporter.nih.gov |
| The Impact of SLC26A9 on Response to CFTR Correction | NIH | National Heart, Lung, and Blood Institute | 2025 | $727,575 | August 15, 2025 | May 31, 2030 | BREWINGTON, JOHN JOSEPH | reporter.nih.gov |
| Climate Change and Longitudinal Lung Function | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $723,929 | May 15, 2024 | April 30, 2028 | COLLACO, JOSEPH MICHAEL | reporter.nih.gov |
| Role of Metallothionein 1 E in the protection of cystic fibrosis-related diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $722,998 | September 1, 2023 | May 31, 2028 | JI, XIANGMING | reporter.nih.gov |
| Function and Regulation of Airway Mucin Glycosylation | NIH | National Heart, Lung, and Blood Institute | 2025 | $702,308 | September 1, 2025 | June 30, 2029 | EVANS, CHRISTOPHER M | reporter.nih.gov |
| Evaluating Maternal and Neonatal Pharmacokinetics of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - The ELECTRA Pregnancy Study | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $696,246 | July 1, 2025 | May 31, 2030 | GUIMBELLOT, JENNIFER S | reporter.nih.gov |
| In vivo delivery of CRISPR Cas9-guide RNA nucleoprotein complexes using the nanoPOD platform | NIH | National Heart, Lung, and Blood Institute | 2021 | $694,345 | September 1, 2019 | July 31, 2022 | TILTON, JOHN CHRISTIAN | reporter.nih.gov |
| Studies on bacteriophages in respiratory diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $654,700 | July 20, 2022 | June 30, 2027 | BOLLYKY, PAUL L | reporter.nih.gov |
| The Role of Macrophage Metabolic Crosstalk in CF Chronic Lung Inflammation | NIH | National Heart, Lung, and Blood Institute | 2023 | $637,263 | September 23, 2023 | August 31, 2025 | ASHARE, ALIX | reporter.nih.gov |
| Neutrophil extracellular traps in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $632,522 | January 1, 2018 | December 31, 2022 | RADA, BALAZS | reporter.nih.gov |
| The impact of Aspergillus species in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $630,176 | July 1, 2019 | June 30, 2025 | HONG, GINA | reporter.nih.gov |
| Tuning translation efficiency to overcome refractory defects in CFTR | NIH | National Heart, Lung, and Blood Institute | 2025 | $629,319 | February 1, 2025 | November 30, 2029 | OLIVER, KATHRYN E | reporter.nih.gov |
| Pseudomonas aeruginosa quorum sensing | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $622,000 | January 5, 2018 | December 31, 2023 | DANDEKAR, AJAI | reporter.nih.gov |
| Rescue of CF phagocyte function with CFTR modulator therapy | NIH | National Heart, Lung, and Blood Institute | 2022 | $611,287 | April 1, 2022 | August 18, 2022 | KOPP, BENJAMIN T | reporter.nih.gov |
| Formulation of a prophylactic vaccine against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,999 | March 16, 2022 | February 28, 2025 | NAGEL, AARON C | reporter.nih.gov |
| Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $597,132 | August 22, 2023 | July 31, 2028 | BURGENER, ELIZABETH BENDIG | reporter.nih.gov |
| A New Quorum-Sensing Autoinducer Acts with the RhIR Receptor to Control Virulence and Biofilms in Pseudomonas Aeruginosa | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $579,890 | September 1, 2018 | August 31, 2023 | MUKHERJEE, SAMPRITI | reporter.nih.gov |
| Impact of virome on microbial communities in the respiratory tract | NIH | National Heart, Lung, and Blood Institute | 2021 | $566,258 | May 1, 2017 | August 31, 2022 | BOMBERGER, JENNIFER MELINDA | reporter.nih.gov |
| Editing basal cells for durable gene therapy of cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $564,121 | August 15, 2025 | May 31, 2029 | GHOSH, DEBADYUTI | reporter.nih.gov |
| The effect of Inhaled Nicotine on Pulmonary Surfaces | NIH | National Heart, Lung, and Blood Institute | 2021 | $557,231 | January 1, 2017 | November 30, 2022 | TARRAN, ROBERT | reporter.nih.gov |
| Receptor-mediated Control of Pulmonary Ionocytes | NIH | National Heart, Lung, and Blood Institute | 2025 | $551,863 | March 15, 2025 | December 31, 2029 | THORNELL, IAN M | reporter.nih.gov |
| Patient-Oriented Research on Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $549,502 | July 10, 2013 | January 31, 2025 | HAUSER, ALAN R | reporter.nih.gov |
| Optimizing ELD607 for Delivery by Inhalation | NIH | National Heart, Lung, and Blood Institute | 2024 | $542,500 | May 15, 2024 | April 30, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Optimizing ELD607 for Delivery by Inhalation | NIH | National Heart, Lung, and Blood Institute | 2025 | $542,500 | May 15, 2024 | April 30, 2027 | TARRAN, ROBERT | reporter.nih.gov |
| Combinatorial design of nonviral base editing systems for treating cystic fibrosis with nonsense mutations | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $540,000 | August 1, 2024 | April 30, 2029 | LI, BOWEN | reporter.nih.gov |
| Genetic basis of metabolite production against clinically-derived pathogens | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $533,809 | May 1, 2018 | August 31, 2025 | WILDSCHUTTE, HANS | reporter.nih.gov |
| Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $524,705 | July 12, 2017 | June 30, 2024 | DI, YUANPU PETER | reporter.nih.gov |
| Targeting inflammation to improve rescue of CFTR by modulator therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $521,392 | May 18, 2023 | March 31, 2028 | BENGTSON, CHARLES | reporter.nih.gov |
| Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $516,456 | February 15, 2020 | December 18, 2023 | GUIMBELLOT, JENNIFER S | reporter.nih.gov |
| CFTR-Independent Bicarbonate Secretion is a Novel CF Therapeutic Target | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $510,389 | April 1, 2020 | March 5, 2024 | SELLERS, ZACHARY MICHAEL | reporter.nih.gov |
| Sweet receptor T1R3 in airway glucose homeostasis and chronic rhinosinusitis | NIH | National Heart, Lung, and Blood Institute | 2025 | $506,420 | September 1, 2025 | May 31, 2029 | LEE, ROBERT J. | reporter.nih.gov |
| SCH: Smart Breath- based Diagnosis of Pulmonary Exacerbations in Children with Cystic Fibrosis through Machine Learning: Towards Noninvasive Health Monitoring in Real-Time | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,621 | September 9, 2024 | May 31, 2028 | AGARWAL, MANGILAL | reporter.nih.gov |
| Personalized Model Systems to Predict and Investigate CFTR Drug Response in CF | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $490,860 | August 1, 2019 | July 31, 2024 | BREWINGTON, JOHN JOSEPH | reporter.nih.gov |
| Optimization of anesthetic/sedative regimen for pulmonary pathophysiology in cystic fibrosis patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $486,750 | February 4, 2021 | January 31, 2024 | YUKI, KOICHI | reporter.nih.gov |
| Identification of novel anti-virulence compounds against Pathogenic Burkholderia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $486,750 | March 17, 2021 | November 30, 2023 | SCHAEFERS, MATTHEW M | reporter.nih.gov |
| Identification of potentiators of antimicrobial activity against multidrug-resistant Burkholderia cepacia complex infections in cystic fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $481,250 | March 1, 2021 | February 28, 2025 | BRENNAN-KROHN, THEA | reporter.nih.gov |
| High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $475,680 | July 21, 2017 | June 30, 2024 | LONGEST, P. WORTH | reporter.nih.gov |
| Patient-oriented microbiome and advanced culture approaches to identifying the microbial determinants of chronic pediatric disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $467,836 | April 22, 2018 | December 31, 2028 | HOFFMAN, LUCAS R | reporter.nih.gov |
| Dynactin 4 regulation of lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 | $466,844 | January 1, 2018 | November 30, 2022 | CHEN, PETER | reporter.nih.gov |
| The roles of the Pseudomonas aeruginosa Prc/AlgO protease - Resubmission - 1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $466,125 | December 7, 2020 | November 30, 2023 | DARWIN, ANDREW J. | reporter.nih.gov |
| Splanchno-Hormonal Mechanisms of Cystic Fibrosis Related Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $463,562 | January 25, 2018 | December 31, 2022 | NORRIS, ANDREW W | reporter.nih.gov |
| Pyocins as antibacterials to treat Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $458,460 | July 1, 2023 | June 30, 2025 | GOLDBERG, JOANNA B | reporter.nih.gov |
| The impact of mucociliary clearance on Mycobacterium tuberculosis pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $456,550 | March 21, 2023 | February 28, 2026 | SHAH, JAVEED ALI | reporter.nih.gov |
| Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic Applications | NIH | National Heart, Lung, and Blood Institute | 2024 | $455,893 | April 1, 2024 | March 31, 2026 | GAO, XUE | reporter.nih.gov |
| Deciphering How Bacterial Surface Properties Influence Social Behaviors | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $453,621 | August 15, 2024 | July 31, 2026 | DIGGLE, STEPHEN PAUL | reporter.nih.gov |
| Reference strains of Mycobacteroides abscessus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $448,849 | April 1, 2021 | March 31, 2024 | LAMICHHANE, GYANU | reporter.nih.gov |
| Bacterial mucin degradation in cystic fibrosis airway disease. | NIH | National Heart, Lung, and Blood Institute | 2021 | $446,311 | August 1, 2017 | May 31, 2023 | HUNTER, RYAN COULSON | reporter.nih.gov |
| A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $444,989 | February 1, 2022 | July 31, 2024 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Intein technology to deliver CFTR to CF airway using AAV | NIH | National Heart, Lung, and Blood Institute | 2025 | $441,375 | August 15, 2025 | July 31, 2027 | MAEDA, YUTAKA | reporter.nih.gov |
| Targeting Multidrug-Resistant Pseudomonas aeruginosa with R Pyocins | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $439,896 | July 16, 2025 | June 30, 2027 | KIRIENKO, NATASHA | reporter.nih.gov |
| Development of a Novel rAAV Vector Without Cross-species Barrier to Transduce Human and Ferret Conducting Airways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $438,238 | June 15, 2021 | May 31, 2024 | QIU, JIANMING | reporter.nih.gov |
| Bioengineered Multi-Cell Type Organoids For Airways Disease Modeling | NIH | National Heart, Lung, and Blood Institute | 2021 | $436,447 | September 1, 2019 | June 30, 2024 | MURPHY, SEAN VINCENT | reporter.nih.gov |
| Identifying mucin O-glycans in the regulation of Staphylococcus aureus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $433,302 | May 3, 2022 | April 30, 2025 | RIBBECK, KATHARINA | reporter.nih.gov |
| Association of Staphylococcus aureus infection with autoimmunity in cystic fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,395 | February 16, 2021 | January 31, 2024 | RADA, BALAZS | reporter.nih.gov |
| Macrophage Pathogen Interactions in Regional Cystic Fibrosis Lung Inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $430,732 | July 1, 2020 | May 31, 2026 | ASHARE, ALIX | reporter.nih.gov |
| Phage extracellular polysaccharide depolymerases to combat Pseudomonas aeruginosa biofilms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,000 | December 1, 2020 | November 30, 2023 | ABEDON, STEPHEN T | reporter.nih.gov |
| Effect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $427,625 | July 20, 2021 | June 30, 2023 | BRAUNSTEIN, MIRIAM S. | reporter.nih.gov |
| CFTR and Vascular endothelial function | NIH | National Institute on Aging | 2025 | $427,625 | September 18, 2025 | August 31, 2027 | KUMAR, SANTOSH | reporter.nih.gov |
| Surface dependent inhibition of Mycobacterium abscessus by Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $427,219 | May 21, 2024 | March 31, 2027 | WOZNIAK, DANIEL J | reporter.nih.gov |
| Mechanism of Prostone Activation During CFTR Modulation | NIH | National Heart, Lung, and Blood Institute | 2022 | $426,793 | September 19, 2022 | August 31, 2024 | ZEITLIN, PAMELA L. | reporter.nih.gov |
| Pseudomonas aeruginosa heme sensing inhibitors targeting HasAp | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | January 22, 2021 | December 31, 2023 | XUE, FENGTIAN | reporter.nih.gov |
| Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $424,875 | July 1, 2023 | June 30, 2026 | SCOTT, ALISON J | reporter.nih.gov |
| An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,595 | September 1, 2023 | August 31, 2025 | PICKING, WENDY L. | reporter.nih.gov |
| In vivo persistence and immuno-pathogenesis of Mycobacterium abscessus in a new Xenopus tadpole model | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $423,500 | April 11, 2022 | March 31, 2024 | ROBERT, JACQUES | reporter.nih.gov |
| Antimicrobial peptides and antibiotic diffusion in sputum | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $423,500 | July 25, 2025 | June 30, 2027 | BOLLYKY, PAUL L | reporter.nih.gov |
| Stenotrophomonas maltophilia TfcA and TfcB: Antibacterial T4SS effectors from an emerging human pathogen | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $420,105 | January 17, 2023 | December 31, 2024 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| CRISPRi-based discovery and in vivo validation of drug targets in M. abscessus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $418,000 | June 9, 2021 | May 31, 2024 | ROHDE, KYLE H | reporter.nih.gov |
| Role of Metallothionein 1 E in the Protection of Cystic Fibrosis-Related Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $412,798 | June 1, 2025 | May 31, 2029 | JI, XIANGMING | reporter.nih.gov |
| Impact of hyperglycemia on the pathogenesis of chronic bacterial lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $411,237 | June 1, 2023 | May 31, 2026 | WOLFGANG, MATTHEW C | reporter.nih.gov |
| Optimal newborn screening algorithms - efficacy and equity | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $409,750 | September 10, 2024 | August 31, 2027 | BISH, DOUGLAS | reporter.nih.gov |
| Impact of mucin fermenting microbes on the virulence of Pseudomonas aeruginosa in chronic rhinosinusitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $408,375 | April 19, 2022 | March 31, 2025 | CHO, DO-YEON | reporter.nih.gov |
| Mechanistic triggers of excessive mucus during lung infections by bacterial volatile organic compounds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $407,208 | August 25, 2023 | July 31, 2026 | LAU, GEE W | reporter.nih.gov |
| An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $406,726 | May 24, 2021 | April 30, 2023 | EMAMINEJAD, SAM | reporter.nih.gov |
| Comparative structural and functional analysis of Pseudomonas aeruginosa inhibitor of vertebrate lysozyme paralogs | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $406,500 | August 26, 2022 | July 31, 2026 | LEEPER, THOMAS C | reporter.nih.gov |
| Role of genetic and epigenetic alterations in CFTR in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $405,711 | July 26, 2021 | June 30, 2024 | PRIZMENT, ANNA | reporter.nih.gov |
| A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis | NIH | National Center for Complementary & Integrative Health | 2023 to 2024 | $404,663 | January 26, 2023 | December 31, 2025 | WOODWORTH, BRADFORD ALAN | reporter.nih.gov |
| The cystic fibrosis sputum compromises the ability of neutrophils to kill Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $403,216 | March 7, 2024 | January 31, 2026 | RADA, BALAZS | reporter.nih.gov |
| Epigenetic Modulation of Cellular Senescence in the Cystic Fibrosis Lung | NIH | National Heart, Lung, and Blood Institute | 2024 | $400,325 | April 1, 2024 | June 30, 2024 | SANDERS, YAN | reporter.nih.gov |
| A novel attachment mechanism for Burkholderia cepacia complex | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $400,125 | February 15, 2023 | January 31, 2026 | HOANG, TUNG T | reporter.nih.gov |
| Commercial Translation of Biomarker-based Platform for Personalized Forecasting of Rapid Lung Function Decline | NIH | National Heart, Lung, and Blood Institute | 2021 | $397,500 | September 1, 2020 | July 31, 2023 | ZIADY, ASSEM G | reporter.nih.gov |
| Polymicrobial interactions in the respiratory tract | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $391,251 | May 1, 2019 | August 31, 2022 | BOMBERGER, JENNIFER MELINDA | reporter.nih.gov |
| High vs Low Glycemic Index Mixed Meal Tolerance Test in Children and Adolescents with Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $391,250 | September 15, 2022 | August 31, 2025 | DALEY, TANICIA | reporter.nih.gov |
| Epigenetic regulation of chemokines in lung inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 | $390,598 | September 1, 2018 | August 31, 2024 | CHEN, KONG | reporter.nih.gov |
| Method Development for Survival Dynamic Regression in Chronic Disease Research | NIH | National Heart, Lung, and Blood Institute | 2021 | $385,193 | August 6, 2012 | April 30, 2024 | PENG, LIMIN | reporter.nih.gov |
| Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets | NIH | National Human Genome Research Institute | 2024 | $384,418 | September 25, 2024 | May 24, 2026 | MIR, KALIM ULLAH | reporter.nih.gov |
| Regulation of the virulence factor PlcH in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $378,790 | August 18, 2023 | July 31, 2024 | WARGO, MATTHEW J | reporter.nih.gov |
| A Novel Proteolytic System of Pulmonary Inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 | $371,250 | July 2, 2010 | December 31, 2022 | GAGGAR, AMIT | reporter.nih.gov |
| Discovery of Novel Nontuberculous Inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $363,750 | July 19, 2021 | June 30, 2025 | NORTH, ELTON JEFFREY | reporter.nih.gov |
| The Microbiota of the Pediatric CF Airway: What role does it play? | NIH | National Heart, Lung, and Blood Institute | 2021 | $363,437 | May 1, 2018 | April 30, 2022 | LAGUNA, THERESA A | reporter.nih.gov |
| A universal genome editing strategy to develop an airway stem cell therapy for cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $333,072 | March 10, 2021 | July 31, 2022 | VAIDYANATHAN, SRIRAM | reporter.nih.gov |
| Improved Tools for Nontuberculous Mycobacteria Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $325,293 | December 12, 2017 | November 30, 2022 | COHEN, KEIRA ALEXIS | reporter.nih.gov |
| Inhibiting CD4+ Th2 development and function by CFTR activity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $321,798 | February 22, 2024 | January 31, 2029 | COOK, DANIEL PAUL | reporter.nih.gov |
| A non-viral nanoparticle gene therapy delivery platform for treating Cystic Fibrosis and other diseases | NIH | National Heart, Lung, and Blood Institute | 2024 | $320,251 | July 1, 2024 | June 30, 2025 | SHEEHAN, COLIN T. | reporter.nih.gov |
| Gene Therapy for Cystic Fibrosis Using Novel Compact Promoters | NIH | National Heart, Lung, and Blood Institute | 2022 | $320,000 | August 10, 2022 | July 31, 2024 | JASKULA-RANGA, VINOD | reporter.nih.gov |
| Stimulation of Ribosomal Frameshifting by Cotranslational Membrane Protein Folding and Misfolding | NIH | National Institute of General Medical Sciences | 2024 | $318,073 | February 1, 2021 | December 31, 2024 | SCHLEBACH, JONATHAN PATRICK | reporter.nih.gov |
| Modulating macrophage-mediated Inflammation in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $315,578 | April 1, 2018 | June 30, 2023 | HISERT, KATHERINE B | reporter.nih.gov |
| Risk Factors For Worse Lung Function In Latinos With Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $314,653 | February 1, 2018 | April 30, 2024 | MCGARRY, MEGHAN ELIZABETH | reporter.nih.gov |
| Novel Selective SGLT-1 Inhibitors for Adjunctive Therapy for Cystic Fibrosis Associated Metabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $306,779 | September 10, 2024 | August 31, 2025 | XU, JIE | reporter.nih.gov |
| Development of a broad spectrum antimicrobial to combat chronic lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 | $300,590 | August 10, 2022 | July 31, 2024 | COOPER, COLLEEN DOYLE | reporter.nih.gov |
| Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,001 | July 23, 2025 | June 30, 2027 | MCGRANE, LAUREL | reporter.nih.gov |
| Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 1, 2020 | May 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,000 | August 15, 2025 | July 31, 2027 | HIBBING, MICHAEL EINER | reporter.nih.gov |
| Computationally-Inspired Design of Non-Viral Gene Delivery Vehicles for mRNA-Based Cystic Fibrosis Therapies | NIH | National Heart, Lung, and Blood Institute | 2023 | $299,995 | August 10, 2023 | July 31, 2025 | MURTHY, SHASHI | reporter.nih.gov |
| HBI-002 for Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $299,975 | April 15, 2024 | March 31, 2026 | GOMPERTS, EDWARD | reporter.nih.gov |
| Wearable Microfluidic Systems for Measuring Sweat Biomarkers in Cystic Fibrosis Patients During Exercise in Remote Settings | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,936 | August 5, 2022 | August 31, 2024 | LEE, STEPHEN PETER | reporter.nih.gov |
| Novel peptide therapeutics to treat cystic fibrosis-related diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $280,122 | September 12, 2025 | June 30, 2028 | SCHOTZINGER, ROBERT | reporter.nih.gov |
| Evolution of Pseudomonas aeruginosa in premise plumbing and impact on cystic fibrosis respiratory disease pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $267,213 | May 1, 2024 | April 30, 2026 | ARMBRUSTER, CATHERINE REBECCA | reporter.nih.gov |
| Tobacco Mosaic Virus as a mucosal delivery platform for an intranasal vaccine against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $261,846 | July 2, 2025 | June 30, 2027 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $254,610 | September 14, 2021 | June 30, 2023 | PIOTROWSKI-DASPIT, ALEXANDRA SARAH ANNUKKA | reporter.nih.gov |
| Defining mechanisms of fungal-bacterial interactions during infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $250,000 | March 7, 2024 | February 28, 2027 | DOLAN, STEPHEN K | reporter.nih.gov |
| Mucin Biosynthesis and Transport Mechanisms in Respiratory Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | August 1, 2025 | July 31, 2028 | JARAMILLO HERNANDEZ, ANA MARIA | reporter.nih.gov |
| Oral dual β-lactams to treat pulmonary M. abscessus disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $245,625 | July 1, 2020 | June 30, 2023 | LAMICHHANE, GYANU | reporter.nih.gov |
| A novel diabetic co-infection model to study pathogen interaction during coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $245,505 | March 19, 2020 | February 28, 2023 | THURLOW, LANCE R. | reporter.nih.gov |
| Impact of Regulatory T Cells on Host Susceptibility to Pseudomonas Aeruginosa Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $239,348 | November 12, 2024 | October 31, 2026 | RIQUELME COLET, SEBASTIAN ALEJANDRO | reporter.nih.gov |
| Characterization of two virulence-associated S. aureus sRNAs | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $236,100 | January 10, 2025 | December 31, 2026 | WHITELEY, MARVIN | reporter.nih.gov |
| Magnetic Microrobots Assist AAV4 for CFTR Gene Delivery Through Mucus Barrier | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $235,500 | May 10, 2025 | March 31, 2028 | LI, JINXING | reporter.nih.gov |
| Using base editing to investigate CFTR polymorphisms in lung diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $234,196 | May 1, 2021 | April 30, 2023 | JIANG, TINGTING | reporter.nih.gov |
| Targeted Macromolecular Antimicrobial Prodrugs Against Pseudomonas Aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $231,674 | August 20, 2020 | July 31, 2024 | ALABI, CHRISTOPHER AKINLEYE | reporter.nih.gov |
| Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $229,499 | January 1, 2020 | December 31, 2022 | GOLDBERG, JOANNA B | reporter.nih.gov |
| A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $227,250 | July 12, 2021 | June 30, 2022 | PICKING, WENDY L. | reporter.nih.gov |
| Drosophila as a model to study modifiers of Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $225,074 | March 3, 2022 | May 1, 2025 | LANE, ELIZABETH | reporter.nih.gov |
| Mucin Biosynthesis and Transport Mechanisms in Respiratory Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $219,306 | April 1, 2023 | March 31, 2026 | JARAMILLO HERNANDEZ, ANA MARIA | reporter.nih.gov |
| In Host Evolution of Nontuberculous Mycobacteria in Cystic Fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $212,584 | February 1, 2020 | January 31, 2023 | PLANET, PAUL J | reporter.nih.gov |
| The role of anaerobic microbiota in cystic fibrosis airway disease trajectory | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $206,534 | July 14, 2023 | November 22, 2023 | HUNTER, RYAN COULSON | reporter.nih.gov |
| Imaging cotranslational protein folding with high spatiotemporal resolution in living cells | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $200,000 | April 1, 2021 | January 31, 2023 | ZHAO, NING | reporter.nih.gov |
| Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $197,396 | July 1, 2019 | March 31, 2023 | O'DONOGHUE, ANTHONY JOHN | reporter.nih.gov |
| A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $195,625 | July 12, 2021 | June 30, 2023 | PICKING, WENDY L. | reporter.nih.gov |
| Iron Deficiency in Cystic Fibrosis: Characterization of Clinical Impact and Treatment Effects | NIH | National Heart, Lung, and Blood Institute | 2025 | $195,459 | August 1, 2025 | July 31, 2030 | JIA, SHIJING | reporter.nih.gov |
| The Impact of a Pseudomonas Bacteriophage on Chronic Biofilm Lung Infections in Cystic Fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $192,672 | September 1, 2025 | August 31, 2030 | KHOSRAVI, ARYA | reporter.nih.gov |
| Mechanisms Underlying the Transduction Polarity of AAV in Polarized Human Airway Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $191,925 | February 13, 2020 | January 31, 2023 | QIU, JIANMING | reporter.nih.gov |
| Surface Active Polyelectrolyte Nanomedicine for Treatment of Lung Infections in Cystic Fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $191,391 | January 24, 2020 | December 31, 2023 | ROTH, CHARLES M. | reporter.nih.gov |
| Adjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $190,000 | June 1, 2020 | May 31, 2023 | JACKSON, MARY | reporter.nih.gov |
| Predicting survival and planning for lung transplantation in severe cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $189,324 | September 15, 2017 | November 30, 2022 | RAMOS, KATHLEEN JESSICA | reporter.nih.gov |
| Alzheimer’s Disease Biomarker for Diagnosis and Prognosis | NIH | National Institute on Aging | 2021 | $188,808 | August 1, 2020 | May 31, 2022 | AMER, AMAL O | reporter.nih.gov |
| Development of small chemical-molecule inhibitors of quorum sensing regulator: a novel treatment for antibiotic resistant bacterial infections. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $187,399 | September 11, 2020 | August 31, 2023 | JADHAV, GOPAL P | reporter.nih.gov |
| Early Childhood Diet, Growth, Gut Microbiome And Lung Health in Cystic Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $177,098 | September 1, 2016 | August 31, 2024 | LAI, HUICHUAN J | reporter.nih.gov |
| Genetic Modifiers and Diagnostics for Bone Health in Cystic Fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $176,040 | September 1, 2025 | August 31, 2030 | WU, MALINDA | reporter.nih.gov |
| Adults with childhood-onset genetic disease: planning for the future amid therapeutic innovation | NIH | National Human Genome Research Institute | 2025 | $174,302 | March 7, 2025 | February 28, 2030 | MUELLER, REBECCA | reporter.nih.gov |
| Targeting Epithelial WNK1 to Enhance Airway Host Defense | NIH | National Heart, Lung, and Blood Institute | 2025 | $169,560 | July 15, 2025 | June 30, 2030 | REHMAN, TAYYAB | reporter.nih.gov |
| The NET effect: Human CF epithelial responses to NETosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $169,312 | September 1, 2017 | August 31, 2022 | HUDOCK, KRISTIN MARA | reporter.nih.gov |
| Changes in Provider Practices for the Management of Cystic Fibrosis (CF) in the Era of Highly Effective Modulator Therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $165,400 | September 23, 2021 | September 22, 2023 | TOPOREK, ALEXANDRA | reporter.nih.gov |
| Carbonic Anhydrase Mediated Regulation of Microtubule Dynamics and Infection in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $163,080 | September 1, 2025 | August 31, 2030 | BOYNE, KATHLEEN L | reporter.nih.gov |
| Mechanisms of impaired mucociliary transport in CF airway disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $160,164 | February 1, 2017 | July 31, 2022 | ABOU ALAIWA, MAHMOUD | reporter.nih.gov |
| Evaluation and Pilot Testing of a Decision Support Tool for Lung Transplant in People Living with Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $155,500 | September 1, 2021 | July 31, 2023 | RAMOS, KATHLEEN JESSICA | reporter.nih.gov |
| Development of tools and knowledge to facilitate the investigation of chloride channel regulator CLCA2 in rare human diseasses | NIH | National Center for Advancing Translational Sciences | 2023 | $155,500 | August 1, 2023 | July 31, 2025 | BRETT, THOMAS JOHN | reporter.nih.gov |
| Leveraging CRISPR RNA-guided DNA Transposases for Gene Insertion at the CFTR Locus | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $153,150 | February 1, 2023 | January 31, 2027 | KING, REBECA TERESA | reporter.nih.gov |
| Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients | NIH | National Heart, Lung, and Blood Institute | 2024 | $150,012 | February 15, 2020 | April 30, 2025 | GUIMBELLOT, JENNIFER S | reporter.nih.gov |
| Elucidating bacterial responses to the novel antimicrobial AGXX | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $148,000 | July 1, 2023 | June 30, 2025 | DAHL, JAN-ULRIK | reporter.nih.gov |
| T cell diversity during chronic inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $146,783 | February 1, 2022 | January 31, 2025 | ROBINSON, KEVEN MARA | reporter.nih.gov |
| Chemically Tunable Mucins to Probe Pathogenic Function in the Epithelial Milieu | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $144,642 | June 1, 2021 | June 30, 2023 | KOHOUT, VICTORIA ROSE | reporter.nih.gov |
| Investigating the role of NMD in Nonsense Mutation Biology and Therapeutic Strategies | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $143,420 | September 1, 2022 | August 31, 2025 | MICHICICH, MARGARET | reporter.nih.gov |
| The Mechanisms Underlying Abnormal Mucus and its Clearance in the Cystic Fibrosis Rat | NIH | National Heart, Lung, and Blood Institute | 2021 | $135,841 | February 1, 2017 | January 31, 2023 | BIRKET, SUSAN ELIZABETH | reporter.nih.gov |
| Investigating the regulation of outer membrane homeostasis in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $130,594 | September 1, 2021 | July 26, 2023 | HUMMELS, KATHERINE RUTH | reporter.nih.gov |
| Determining the role of cyclic-di-GMP in Pseudomonas aeruginosa's transition to the nutritional environment of the cystic fibrosis lung | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $113,190 | March 9, 2022 | March 8, 2025 | MORRIS, ROXANNE | reporter.nih.gov |
| Overcoming Immunological Barriers to Inhaled AAV Gene Therapy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $106,958 | September 30, 2024 | August 29, 2029 | CLARK, ROBERT DAVID EDWARD | reporter.nih.gov |
| Modulation of ribosome velocity as a means to rescue refractory CF-causing variants | NIH | National Heart, Lung, and Blood Institute | 2021 | $105,424 | April 1, 2020 | August 31, 2021 | OLIVER, KATHRYN E | reporter.nih.gov |
| Strategies towards the Synthesis of Azetidine-Containing Metabolites Produced by Pseudomonas aeruginosa | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $102,185 | April 1, 2023 | September 10, 2024 | DORN, STANNA | reporter.nih.gov |
| Host-Pathogen Interactions in a Cystic Fibrosis Polymicrobial Infection Model | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $98,512 | January 1, 2024 | December 31, 2026 | CHARPENTIER, LILY | reporter.nih.gov |
| Cross-fed metabolites modulate Pseudomonas aeruginosa fitness | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $98,512 | September 1, 2024 | August 31, 2026 | CONAWAY, AMY CAROLYN | reporter.nih.gov |
| Expectations and Outcomes of Healthcare Transition in Adolescents and Young Adults with Cystic Fibrosis | NIH | National Institute of Nursing Research | 2021 to 2022 | $85,100 | September 16, 2021 | June 15, 2023 | MELTON, KATHERINE T | reporter.nih.gov |
| Optimizing exercise for cystic fibrosis: Understanding immune modulation and identifying blood biomarkers | NIH | National Institute on Aging | 2025 | $84,166 | September 23, 2025 | August 31, 2026 | JANUSKA, MEGAN | reporter.nih.gov |
| Sputum-Based Profiling to Predict Cystic Fibrosis Exacerbations | NIH | National Heart, Lung, and Blood Institute | 2021 | $83,750 | August 15, 2020 | July 31, 2023 | BRITTO-LEON, CLEMENTE | reporter.nih.gov |
| Advancing lentiviral gene therapy for cystic fibrosis. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $82,722 | July 10, 2020 | May 12, 2023 | MARQUEZ LOZA, LAURA ISABEL | reporter.nih.gov |
| Therapeutic potential of CC-90009 for cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $81,804 | September 1, 2024 | August 31, 2029 | BULIK-SULLIVAN, EMILY CLAIRE | reporter.nih.gov |
| Environmental acquisition of ST398 Staphylococcus aureus by patients with chronic respiratory disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $77,750 | August 1, 2025 | July 31, 2027 | FISCHER, ANTHONY JOHN | reporter.nih.gov |
| New biophysical and immunoregulatory mechanisms in neutrophil extracellular trap mediated lung dysfunction in cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $77,060 | September 16, 2024 | September 15, 2026 | BOBOLTZ, ALLISON MARGARET | reporter.nih.gov |
| Characterization and engineering of a compact genome editor for adeno-associated virus delivery to correct mutations causing cystic fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $76,890 | August 1, 2021 | May 31, 2023 | TSUCHIDA, CONNOR ANDREW | reporter.nih.gov |
| SPLUNC1 and Neutrophilic Inflammation in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $69,930 | June 1, 2021 | January 9, 2022 | BRITTO-LEON, CLEMENTE | reporter.nih.gov |
| Fate Specification of CFTR High Expresser Cells in the Intestine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $68,408 | February 1, 2024 | January 31, 2026 | ZAGOREN, ELEANOR | reporter.nih.gov |
| Engineering Human Bronchial Epithelial Cells for Cystic Fibrosis Cell Therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $67,077 | July 1, 2021 | May 31, 2023 | LEE, RHIANNA E | reporter.nih.gov |
| The Role of Defective CFTR Ion Transport on Mucin Sialylation and its Consequences on Mucus Physiology | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $60,388 | July 1, 2022 | January 31, 2024 | HARRIS, ELEX S | reporter.nih.gov |
| Molecular Chaperone Recognition of CFTR Stability | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $58,212 | September 1, 2022 | May 31, 2024 | MCDONALD, ELI FRITZ | reporter.nih.gov |
| Interactions between Pseudomonas aeruginosa and Streptococcus salivarius and effects on the host immune response | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $57,115 | February 1, 2022 | August 18, 2023 | STONER, SARA N | reporter.nih.gov |
| Pharmacological inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $54,538 | July 9, 2025 | July 8, 2029 | YOUNG, PAUL | reporter.nih.gov |
| Elucidating premature translation termination in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $52,987 | May 1, 2020 | December 19, 2022 | CARBONE, CHRISTINE ELIZABETH | reporter.nih.gov |
| Dual function for an effector immunity protein in Pseudomonas aeruginosa biofilm biogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $52,538 | August 1, 2025 | July 31, 2027 | MICHAELS, LIA A | reporter.nih.gov |
| Antisense-oligonucleotide-directed inhibition of nonsense-mediated mRNA decay of CFTR gene | NIH | National Heart, Lung, and Blood Institute | 2021 | $51,036 | August 1, 2018 | July 31, 2022 | KIM, YOUNG JIN | reporter.nih.gov |
| The Role of Airway Microbiota in Nontuberculous Mycobacterial Infection in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $50,952 | May 1, 2021 | January 9, 2022 | CAVERLY, LINDSAY J | reporter.nih.gov |
| Investigating R-pyocins as a therapeutic approach to treat high-risk, multidrug-resistant Pseudomonas aeruginosa wound infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $49,538 | August 15, 2025 | August 14, 2028 | ESTRADA, ISAAC | reporter.nih.gov |
| Leveraging a 'sliding-window' Type I CRISPR base editing platform to correct CFTR null mutations | NIH | National Heart, Lung, and Blood Institute | 2025 | $43,589 | January 1, 2025 | December 31, 2027 | MYERS, MASON T | reporter.nih.gov |
| Inhibiting CD4+ Th2 development and function by CFTR activity. | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $42,752 | February 22, 2024 | June 27, 2024 | COOK, DANIEL PAUL | reporter.nih.gov |
| Influenza Mediated ER Stress and Secondary Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $42,574 | August 1, 2024 | July 31, 2026 | EARNHARDT, ERIN YEPSEN | reporter.nih.gov |
| CFTR gene correction via targeted exon replacement | NIH | National Heart, Lung, and Blood Institute | 2025 | $41,057 | January 1, 2026 | December 31, 2028 | BUFFINGTON, JESSE | reporter.nih.gov |
| Identification of Cross-Protective Surface Antigens in Burkholderia Species | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $38,936 | July 1, 2025 | June 30, 2027 | BADTEN, ALEXANDER JESSE | reporter.nih.gov |
| Prostones as novel receptor-mediated activators of CFTR in the airway | NIH | National Heart, Lung, and Blood Institute | 2021 | $32,997 | May 1, 2021 | October 31, 2021 | SHAUGHNESSY, CIARAN | reporter.nih.gov |
| 2025 Cilia, Mucus and Mucociliary Interactions Gordon Research Conference and Gordon Research Seminar | NIH | National Heart, Lung, and Blood Institute | 2025 | $25,000 | January 1, 2025 | December 31, 2025 | RIBBECK, KATHARINA | reporter.nih.gov |
| Rare Genetic Causes of Bronchiectasis: Paving the Way for Interventional Trials | NIH | National Heart, Lung, and Blood Institute | 2021 | $19,959 | February 15, 2021 | January 31, 2022 | KINGHORN, BREANNA | reporter.nih.gov |
| Mixed Methods Approach to Evaluating Barriers to Nutritional Adherence in Adolescents with Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 | $13,670 | March 15, 2020 | July 31, 2022 | DURKIN, KRISTINE | reporter.nih.gov |
| Colorado Mycobacteria Conference: Focus on NTM | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $12,000 | August 1, 2021 | July 31, 2022 | CRICK, DEAN C | reporter.nih.gov |
| Regulatory Role of Chromosome 11p13 in Cystic Fibrosis Lung Disease Severity | NIH | National Heart, Lung, and Blood Institute | 2021 | $6,670 | May 1, 2019 | June 30, 2021 | SWAHN, HANNAH | reporter.nih.gov |
| Chemical Biology of CFTR Regulation | NIH | National Heart, Lung, and Blood Institute | 2021 | $2,500 | July 15, 2021 | July 21, 2021 | INFIELD, DANIEL T | reporter.nih.gov |
| Effects of an anti-diabetes diet on bone health in adults with cystic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $1 | May 1, 2024 | May 2, 2024 | KINDLER, JOSEPH | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 145 | $71,600,676 | 0 | $0 |
| 2024 | 156 | $68,342,853 | 0 | $0 |
| 2023 | 153 | $68,702,754 | 0 | $0 |
| 2022 | 164 | $72,208,673 | 0 | $0 |
| 2021 | 176 | $69,099,095 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.